Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s):  AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.


CSE:AGN - Post by User

Comment by nodaytraderon Jan 31, 2022 2:25pm
124 Views
Post# 34380044

RE:RE:RE:Expect Nothing Less Than Inexplicable Price Action @ CSE/OTC

RE:RE:RE:Expect Nothing Less Than Inexplicable Price Action @ CSE/OTCSo many criticisms, although I appreciate your taking the time to post.

To begin with, we agree that the NASDAQ uplift is essental but, to repeat, while this will solve the problem for Algernon,  trading remains a problem for other companies. It is probably a good trhing to have a Canadian exchange for small start-ups but why does that exchange have to be perilous? 

There are predatory sharks in Australian coastal waters but the local authorities put up shark nets to protect bathers. Why can't our authorities provide some protection for vulnerable start-ups? Why should we have to rely on an American exchange to solve a Canadian problem?

I can identify the players but choose not to, for two reasons. One is that I shouldn't have to. You only have to look at the activity to see what is going on. The second is to avoid any possible legal action. The way the system works the process is punishment - even when you win. I speak from experience.

The recent market meltdown is not relevant. The problems that I see Algernon having have been going on for years.

I did read the Code of Conduct on its release but did not see anthing significant that is not already implcit in corporate fiduciary responsibilities.


<< Previous
Bullboard Posts
Next >>